News

Adults with myelofibrosis whose disease no longer responded to or who could not tolerate Jakafi (ruxolitinib) or other Janus kinase (JAK) inhibitors showed signs of clinical benefit with the investigational therapy selinexor in a small Phase 2 study. The therapy also proved safe and well tolerated. The…

Adults with myelofibrosis who received a two-step donor stem cell transplant saw their blood counts recover faster and lived longer than patients who received a traditional one-step transplant. Those are the findings of a new study by scientists at Thomas Jefferson University in Philadelphia that compared outcomes among…

Halozyme Therapeutics and Incyte are partnering to develop an under-the-skin (subcutaneous) formulation of INCA033989, Incyte’s therapy candidate for people with myeloproliferative neoplasms, including myelofibrosis — a type of slow-growing blood cancer. The goal for the two U.S.-based developers is to create a simpler and potentially more convenient…

Adults with myelofibrosis who received the experimental therapy navitoclax together with Jakafi (ruxolitinib) were about twice as likely to experience a clinically meaningful reduction in spleen size as those treated with Jakafi alone, according to results from the Phase 3 TRANSFORM-1 clinical trial. The combination therapy did not…

An experimental form of immunotherapy could identify and eliminate cancer-driving blood cells harboring a specific mutation while sparing most healthy cells, making it a promising therapeutic strategy for myelofibrosis and related cancers, a study found. The study, led by researchers at University College London (UCL) and the University…

Eli Lilly’s AJ1-11095, an experimental JAK2 inhibitor recently licensed from Ajax Therapeutics, may be safe and effective at easing symptoms of myelofibrosis in patients whose disease has stopped responding to first-generation JAK2 inhibitors. That’s according to initial results from AJX-101 (NCT06343805), an open-label Phase 1 clinical…

Treatment with Disc Medicine’s investigational therapy DISC-0974 was tied to easing of fatigue, as well as a drop in overall symptoms, among certain myelofibrosis patients with cancer-associated anemia in a clinical trial called RALLY-MF. Updated results from the trial’s Phase 2 portion show that half of the major responders…

Adding the investigational therapy selinexor to an approved regimen of Jakafi (ruxolitinib) in the Phase 3 SENTRY trial led to a greater reduction in spleen size and may have improved survival for participants with myelofibrosis, according to selinexor’s developer, Menarini Group. “The strength of the spleen…

An elderly woman with primary myelofibrosis experienced disease worsening despite being on treatment with hydroxyurea and was later found to have a rare mutation in the CALR gene that had been missed by routine genetic testing. According to clinicians, the woman’s “clinical progression prompted repeat [blood] and molecular evaluation,” with…

Circulating myeloblasts (CMB), a type of immature white blood cell commonly found in the bloodstream of people with myelofibrosis, may serve as a marker of disease severity and outcomes, according to a pilot study. Blood levels of myeloblasts, measured by a sensitive technique called flow cytometry, correlated with established…